WHO interim guidance on the use of bedaquiline to treat MDR-TB
Submitted by susan on Mon, 2013-07-01 12:42
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis (MDR-TB) occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB. Globally, less than half of all patients who start MDR-TB therapy are treated successfully.
Main Topic:
Mark Content Private(Internal):
External URL:
http://www.who.int/mediacentre/news/notes/2013/bedaquiline_mdr_tb_20130613/en/
Email Alert:
Publication Date:
13/06/2013